tirzepatide in the news Twincretin drug shows unmatched efficacy weight loss and diabetes management Tirzepatide has been officially removed

Unlike traditional human growth hormone therapy, which can cause increased levels of insulin-like growth factor-1 (IGF-1) and affect blood sugar regulation, AOD-9604 is designed to target fat cells directly

Recently, two novel therapeutic classes have emerged: sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists

Gastrointestinal Side Effects: Common issues include nausea, vomiting in a few, diarrhea or constipation, particularly when starting treatment or increasing the dose

The oral formulations real impact depends on pricing and reimbursement decisions that are years away